Flow cytometry validation identified CD73 as a useful marker to monitor minimal residual disease (MRD) as its expression correlated quite precisely to that of molecular markers already in use to predict ALL relapse. The gene discussed is NT5E; the disease is acute lymphoblastic leukemia.